You are here: Industry Insights > PONVORY

News List

MHRA nod for Janssen’s relapsing multiple sclerosis drug Ponvory pharmatimes
August 12, 2021
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Ponvory (ponesimod) for the treatment relapsing multiple sclerosis (RMS).
EC approves Ponvory for relapsing MS pharmatimes
May 26, 2021
The European Commission (EC) has cleared Janssen’s Ponvory for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease.
European Commission approves PONVORY™ --- A Once Daily Oral Treatment for Adults with Relapsing Forms of Multiple Sclerosis americanpharmaceuticalreview
May 25, 2021
Janssen, the Pharmaceutical Companies of Johnson & Johnson, announced that the European Commission (EC) has approved PONVORY™ (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by ...
Five new meds recommended in March CHMP decisions pharmatimes
March 30, 2021
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended five new medicines for approval at its March meeting, as well as six recommendations of current indications.
US FDA approves Janssen’s PONVORY for relapsing multiple sclerosis pharmaceutical-technology
March 23, 2021
The US Food and Drug Administration (FDA) has approved the Janssen Pharmaceutical Companies of Johnson & Johnson’s (JNJ) PONVORY (ponesimod) for treating adults with relapsing forms of multiple sclerosis (MS).